Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 8/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19668231 | 0.98 | APP (0.44) | APPADORA2AGRM5NPC1RAB9A | |
| SCHEMBL29994138 | 0.78 | NOS3 (0.45) | GRM5NPC1RAB9AKDM4ENOS3 | |
| SCHEMBL23704358 | 0.78 | NOS3 (0.45) | GRM5NPC1RAB9AKDM4ENOS3 | |
| SCHEMBL30491595 | 0.78 | NOS3 (0.35) | GRM5NPC1RAB9AKDM4ENOS3 | |
| SCHEMBL28950071 | 0.77 | APP (0.46) | APPADORA2AGRM5KDM4EALDH1A1 | |
| SCHEMBL3883842 | 0.77 | MAPT (0.52) | APPADORA2AGRM5NPC1SMN1; SMN2 | |
| SCHEMBL1906166 | 0.77 | EGFR (0.52) | APPADORA2AGRM5 | |
| SCHEMBL15966340 | 0.74 | NOS3 (0.42) | GRM5NPC1RAB9AKDM4ENOS3 | |
| SCHEMBL15775225 | 0.74 | APP (0.43) | APPADORA2AGRM5NPC1SMN1; SMN2 | |
| SCHEMBL30521933 | 0.74 | APP (0.43) | APPADORA2AGRM5NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | claimed |
| WO-2009143404-A1 | PIPERAZINE METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLUR5) NEGATIVE ALLOSTERIC MODULATORS FOR ANXIETY/DEPRESSION | WYETH (US) | 2009-11-26 | — | — | WO | claimed |
| US-20130123248-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-16 | — | — | US | disclosed |
| EP-2473166-A2 | TREATMENT AND PREVENTION OF SECONDARY INJURY AFTER TRAUMA OR DAMAGE TO THE CENTRAL NERVOUS SYSTEM | Schneider, Eric B. (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20120157420-A1 | TREATMENT AND PREVENTION OF SECONDARY INJURY AFTER TRAUMA OR DAMAGE TO THE CENTRAL NERVOUS SYSTEM | SCHNEIDER ERIC B (US) | 2012-06-21 | — | — | US | disclosed |
| US-20110306601-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-15 | — | — | US | disclosed |
| WO-2011026060-A2 | TREATMENT AND PREVENTION OF SECONDARY INJURY AFTER TRAUMA OR DAMAGE TO THE CENTRAL NERVOUS SYSTEM | SCHNEIDER ERIC B (US) | 2011-03-03 | — | — | WO | disclosed |
| US-20100234402-A1 | METHODS AND COMPOSITIONS FOR TREATING SPINAL MUSCULAR ATROPHY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2010-09-16 | — | — | US | disclosed |
| US-20090192199-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-07-30 | — | — | US | disclosed |
| WO-2009016486-A2 | USE OF NMDA RECEPTOR ANTAGONISTS FOR TREATMENT OF UROLOGIC TUMORS | COMPUGEN, LTD (US) | 2009-02-05 | — | — | WO | disclosed |
| EP-2010174-A2 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | The Regents of the University of California (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2008150509-A1 | METHODS AND COMPOSITIONS FOR TREATING SPINAL MUSCULAR ATROPHY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2007124348-A2 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007035823-A2 | PARTIAL MGLUR5 ANTAGONISTS AND METHODS OF USE THEREOF | MOLECULAR NEUROIMAGING, LLC (US) | 2007-03-29 | — | — | WO | disclosed |
| US-20060286167-A1 | Compositions and methods for the treatment of neurodegenerative diseases | STAUNTON JANE | 2006-12-21 | — | — | US | disclosed |
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | COMBINATORX, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006119329-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | COMBINATORX, INCORPORATED (US) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006119295-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | COMBINATORX, INCORPORATED (US) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | GRM5, GRIK5, GRM1 | APP 2358/4885ADORA2A 193/4885GRM5 1/4885 |
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | PSEN2, PSEN1, HTT | APP 14/4885ADORA2A 629/4885GRM5 269/4885 |
| US-20090192199-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | GRM1, GRM2, GRIN1 | APP 2775/4885ADORA2A 454/4885GRM5 13/4885 |
| US-20110306601-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | GRM1, GRM2, GRIN1 | APP 2745/4885ADORA2A 478/4885GRM5 15/4885 |
| US-20130123248-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | GRM1, GRM2, GRIN1 | APP 2745/4885ADORA2A 478/4885GRM5 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.